EVIDEnCe-SCD
Research type
Research Study
Full title
A pilot observational study to evaluate and characterise the role that extracellular vesicles and cell-free DNA play during inflammatory processes such as vaso-occlusive crises in Sickle Cell Disorder
IRAS ID
361202
Contact name
Kathryn Simpson
Contact email
Sponsor organisation
Whittington Health
Duration of Study in the UK
2 years, 0 months, 0 days
Research summary
Sickle cell disorder (SCD) is an inherited blood condition affecting around 17,000 people in the UK and 8 million persons worldwide. The primary event of the disorder is where the haemoglobin (the compound which delivers oxygen to tissues) polymerizes leading to red blood cell becoming stiff, fragile and sickle shaped, in times of physiological stress this process is increased leading to occlusion in the blood vessels and inflammation which, translates to painful episodes called vaso-occlusive crises (VOCs). These crises can be severe, requiring hospital care, and this process can also occur in vital organs such as the lungs and brain leading to respiratory failure and stroke respectively. However, the frequency and severity of crises vary greatly between individuals, and the reasons for this are not yet understood. A lack of research in this area has contributed to ongoing health inequalities affecting people with SCD.
This pilot study will focus on two types of molecules in the blood that may be involved in these crises: extracellular vesicles (EVs) and cell-free DNA (cfDNA). EVs are tiny particles released by cells that can carry molecules and influence inflammation and blood clotting. cfDNA consists of fragments of DNA released into the bloodstream during cell damage or inflammation. Both may play roles in the pathophysiology of VOCs.
We aim to develop laboratory methods to measure and analyse EVs and cfDNA in blood samples from people with SCD, by collecting a blood sample during stable periods and during a VOC. This will help us understand whether changes in these markers are linked to the onset or severity of crises.
The findings will form the basis for larger studies to explore EVs and cfDNA as possible biomarkers—tools that could help predict the severity of acute complications or even may serve as new therapeutic targets in the management of sickle cell disorder.REC name
London - South East Research Ethics Committee
REC reference
26/LO/0041
Date of REC Opinion
6 Mar 2026
REC opinion
Further Information Favourable Opinion